ITF
Desconocido
IMPACT: Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagn...
ITALFARMACO SPA
participó en un
HORIZON EUROPE:
HORIZON-EIC-2022-PATHFINDERCHALLENGES-01
Arrhythmogenic cardiomyopathy (ACM) is a genetic disease characterized by progressive cardiomyocyte loss and fibrofatty replacement, which i...
2023-06-20 - 2026-09-30 | Financiado
2023-06-20 - 2026-09-30 | Financiado
ENDOSTEM: Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance...
We propose to develop new strategies to mobilize skeletal muscle tissue-associated stem cells as a tool for efficient tissue repair. This wi...
Financiado
Financiado
* No se disponen de datos de la empresa actual.